Hepatobiliary Malignancies

Sorafenib inhibits signal transducer and activator of transcription‐3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2†

Blechacz, Boris R. A.1; Smoot, Rory L.1; Bronk, Steven F.1; Werneburg, Nathan W.1; Sirica, Alphonse E.2; Gores, Gregory J.*,1,‡

Author Information

1Miles and Shirley Fiterman Center for Digestive Diseases, Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Rochester, MN

2Department of Pathology, Division of Cellular and Molecular Pathogenesis, Virginia Commonwealth University School of Medicine, Richmond, VA

College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905===

Received June 15, 2009

Accepted July 28, 2009

Hepatology 50(6):p 1861-1870, December 2009. | DOI: 10.1002/hep.23214
Copyright © 2009 American Association for the Study of Liver Diseases.

Full Text Access for Subscribers:

AASLD members log in here
AASLD members log in here

Not a Subscriber?

Buy
Request Permissions
Become a Society Member

You can read the full text of this article if you:

Access through Ovid